The new diabetes test helps identify patients with type 1 diabetes The FDA has approved empagliflozin/linagliptin tablets as an adjunct to diet and exercise to ...

Ingelheim, Germany and Indianapolis, US, 16 September, 2014 – Boehringer Ingelheim and Eli Lilly and Company today presented results from a 52-week Phase III study ...

The investigational combination tablet of empagliflozin and linagliptin reduced blood glucose levels in patients with type 2 diabetes as presented by Boehringer Ingelheim and Eli Lilly and Company at ...

Ahmedabad: Zydus Lifesciences Limited has received tentative approval from the United States Food and Drug Administration (USFDA) for Empagliflozin and Linagliptin Tablets, 10 mg/5 mg and 25 ...

Glyxambi Approved for Type 2 Diabetes The Food and Drug Administration (FDA) has approved Glyxambi (empagliflozin/linagliptin tablets; Boehringer Ingelheim and Eli ...

The company plans to manufacture these tablets at its formulation manufacturing facility situated in the SEZ in Ahmedabad.

GLYXAMBI is not recommended in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. GLYXAMBI has not been studied in patients with a history of pancreatitis, and it is unknown ...

Generic versions of the popular diabetes drug Empagliflozin have reached the market after Boehringer Ingelheim's patient ...

RIDGEFIELD, Conn. and INDIANAPOLIS, June 15, 2014 -- Two phase III clinical trials found the investigational combination tablet of empagliflozin and linagliptin reduced blood glucose levels in adults ...

- For those taking metformin, empagliflozin/linagliptin combination tablet showed statistically significant reductions in blood glucose vs. empagliflozin or ...